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T cell activation and proliferation critical for protective immunity depend on appropriate rewiring of cellular
metabolism. In this issue of Immunity, Mak et al. (2017) show that the antioxidant gluthathione (GSH) controls
reactive oxygen species (ROS)-dependent engagement of metabolic signaling pathways that lead to protec-
tive T cell responses.Reactive oxygen species (ROS) was first
thought of as a damaging byproduct of
oxidative metabolism, but there are also
positive roles for ROS as a signalingmole-
cule in T cell activation. ROS generated in
themitochondrial electron transport chain
(ETC) is critical for activation of NFAT, a
T cell-specific transcription factor that
mediates interleukin-2 (IL-2) production
and engagement of the cell cycle, allow-
ing for rapid proliferation (Sena et al.,
2013). This function of ROS is in stark
contrast with its capacity to damage
RNA, DNA, and proteins, which can lead
to cell death or enhanced carcinogenesis
(Sabharwal and Schumacker, 2014).
Thus, controlling ROS concentrations is
critical for cellular activation, function,
and health.
The expression of metabolic modula-
tors like thioredoxin and glutathione
(GSH) can limit ROS activity. The main
cellular mop for superoxides is GSH,
which is synthesized from cysteine, gluta-
mic acid, and glycine in a two-step, ATP-
dependent reaction (Chen et al., 2005).
The rate-limiting enzyme for GSH syn-
thesis is glutamate cysteine ligase (GCL),
which has a catalytic (GCLC) and amodu-
latory (GCLM) domain. Genetic deletion of
Gclc is embryonic lethal, whereas the
GCLM subunit is required neither for
GSH generation nor survival of mice. In
T cells, GCLC is transcriptionally induced
after activation through the T cell receptor
(TCR), increasing the cellular concentra-
tion of GSH.
To address the role of transcriptional
upregulation of GCLC after T cell activa-
tion, Mak et al. (2017) deleted Gclc in
T cells, thereby abrogating GSH syn-
thesis only in T cells and bypassing the
lethality of the global genetic deletion.Absence of GSH led to modest increases
in ROS but did not affect downstream
TCR signaling nor the expression of sur-
face markers associated with T cell acti-
vation. However, GCLC-deficient T cells
failed to increase in size and engage
the proliferative burst associated with
full T cell activation. This suggests that
the absence of GSH in T cells does not
interfere with TCR signaling per se, but
leads to a failure to reprogram the
cellular machinery needed for robust
clonal expansion.
T cell receptor signaling leads to
rapid transcriptional changes. However,
T cells do not divide until many hours
later, suggesting a lag phase that ‘‘pre-
pares’’ cells for ensuing proliferation.
While naive T cells use oxidative meta-
bolism to support homeostatic prolifera-
tion, the biomass required for clonal
expansion is facilitated by the engage-
ment of aerobic glycolysis. This pre-
proliferative phase of T cell metabolic
reprogramming is linked to enhanced
phosphoinositol-3-kinase (PI3K)-depen-
dent glucose import (Frauwirth et al.,
2002) and glutamine uptake through
Myc-dependent induction of CD98
(Wang et al., 2011). Despite the apparent
normalcy of TCR signaling during early
activation, the lack of GSH in T cells pre-
vented the induction of aerobic glycolysis
and the increase in cell size associated
with T cell activation.
Both increase in cell size and engage-
ment of the cell cycle are controlled by
the mechanistic target of rapamycin
(mTOR) signaling axis (Saxton and Saba-
tini, 2017), whichMak et al. (2017) showed
to be blunted in the absence of GSH. This
inhibition of mTOR signaling was reversed
by treatment of GCLC-deficient cells withImmunityROS scavengers, which demonstrated
that increased ROS inhibits mTOR
signaling. mTOR exerts its function as a
catalytic subunit of larger multiprotein
complexes that integrate intra- and extra-
cellular signals linked to nutrient availabil-
ity into a metabolic readout that has been
extensively linked to the activation of
T cells (Powell et al., 2012).
One of the key targets of mTORC1 is
Myc, a transcription factor that activates
many target genes, including those in
T cells that lead to metabolic reprogram-
ming during the lag-phase after TCR
activation (Wang et al., 2011). NFAT,
which drives IL-2 expression after TCR
ligation, is also influenced by cellular
ROS (Sena et al., 2013). NFAT is regu-
lated by calcium-dependent calcineurin
signaling, leading to nuclear transloca-
tion and activation of target genes,
including Myc.
Lack of GSH blunted the expression
and nuclear localization of NFAT and
reduced Myc protein expression, both
of which could be reverted by ROS
scavengers. Reduced NFAT and Myc
activity in combination with a block in
mTOR signaling led to decreased meta-
bolic engagement, as shown by reduced
glutamine and glucose uptake and
reduced cellular ATP. After activation,
GCLC-deficient cells doubled the incor-
poration of carbons from fatty acids,
while the incorporation of carbons from
glucose and glutamine was reduced—a
metabolic phenotype more consistent
with non-proliferative naive T cells.
GCLC-deficient cells utilized carbon
sources other than palmitate, glutamine,
or glucose to generate Krebs cycle inter-
mediates. The lack of labeled carbon
incorporation in these assays could46, April 18, 2017 ª 2017 Elsevier Inc. 525
Figure 1. TCR Activation in WT Cells Leads to an Increase in Cellular ROS Concentrations
that Can Be Buffered by the Antioxidant GSH
GSH synthesis increases after TCR activation through transcriptional induction of the glutamate
cysteine ligase catalytic subunit (GCLC). GSH limits ROS activity to allow ROS-dependent activation of
NFAT, but also prevents excessive ROS accumulation that can have damaging side effects. GSH-
mediated buffering allows for activation of the critical metabolic mediators calcium-dependent calci-
neurin, NFAT, Myc, and mTOR. This in turn rewires metabolism and increases aerobic glycolysis
and glutamine import, to support biomass generation for cell growth and proliferation. TCR activation
in Gclc/ T cells leads to an increase in cellular concentrations of ROS, which can no longer be
adequately buffered. Increased ROS concentrations interferes with activation of NFAT, Myc, and
mTOR. Failure to induce enhanced glycolysis and glutamine import in Gclc/ T cells leads to reduced
cell growth and proliferation. Proper metabolic remodeling is essential for the formation of protective
immune responses in vivo.
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Previewspoint to a metabolic switch to other
extracellular carbon sources or to an in-
crease in reallocation of carbon sources
generated through autophagy, which is
activated by substrate limitation in the
absence of mTOR signaling. The lack
of cell death until 48 hr after activation
in the absence of GCLC revealed that
these cells remain viable, which could
be achieved by engaging autophagy
(Pua et al., 2007). Autophagy might
pause proliferation of the cells in the
absence of correct metabolic reprog-
ramming in an attempt to compensate
for deficiencies in glutamine and glucose
metabolism. The question remains
whether GCLC-deficient T cells can be
rescued from this intermediate state of
activation by scavenging ROS after
initial activation, presumably through in-
duction of the proper metabolic state
via Myc.
The reduction of NFAT in the GCLC-
deficient T cells limited the expression of
Myc, but also seemed to be upstream of526 Immunity 46, April 18, 2017mTOR activation. Treatment of T cells
with the calcineurin inhibitor FK506 during
activation led to an abrogation of mTOR
target phosphorylation. The strength of
mTOR signals was reduced to a much
greater extent by blocking calcineurin
when compared to treatment with the
mTOR inhibitor rapamycin. This suggests
that the activation of calcineurin is the
rate-limiting factor for NFAT expression,
Myc expression, and mTOR activation
during the lag phase of T cell activation
(Figure 1).
In tumor cells, it was reported that
increased Myc expression induces
ROS, leading to DNA damage and
enhanced tumorigenic mutation rates
(Vafa et al., 2002). The current report
puts Myc expression downstream of
ROS scavenging by GSH in primary
T cells. This could reduce the risk of
increased ROS-mediated mutations and
carcinogenic transformation of rapidly
proliferating cells expressing high
amounts of the proto-oncogene Myc.Retroviral expression of Myc led to
engagement of proliferation independent
of GSH. This proliferation was still sensi-
tive to the inhibition of calcineurin, sug-
gesting that exogenous expression of
Myc cannot substitute for the Myc-inde-
pendent signals conferred by calcineurin,
highlighting the importance of calcium-
dependent activation of calcineurin tar-
gets besides Myc. This finding could
pinpoint calcineurin as a potential thera-
peutic target in Myc-driven pathologies
in T cells, even in the context where dys-
regulated Myc is no longer under the
transcriptional control of NFAT.
High ROS concentrations in the
absence of GSH buffering blunted
T cell activation and resulted in a bene-
ficial effect that prevented autoimmune
pathology in a mouse model of multiple
sclerosis. However, it has also been
shown that when ROS is ablated, there
is enhanced susceptibility to viral infec-
tion in vivo (Sena et al., 2013). Taken
together, the data suggest that incor-
rect ROS titration negatively affects
NFAT activity, mTOR signaling, and
Myc protein expression and imply that
ROS modulates metabolic cues during
T cell fate decisions in vivo. Whether
cell-intrinsic or -extrinsic factors that
directly modulate ROS in T cells in vivo
impact metabolic regulation of differen-
tiation is an intriguing avenue for
investigation and potential therapeutic
modulation.
Rewiring metabolism after T cell activa-
tion increases energy expenditure and in-
creases potentially damaging ROS. When
ROS concentrations are either too high or
too low, a block in metabolic rewiring ob-
structs T cells from growth and entering
the cell cycle (Figure 1). The antioxidant
GSH tempers ROS activity to a sweet
spot, which allows T cells to enter the
cell cycle, metabolically reprogram,
differentiate, and form protective immune
responses. Thus, ROSmanipulates meta-
bolic progress; too much is catastrophic,
but when applied correctly, it can be life
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The persistence of viruses ‘‘hidden’’ in a reservoir of latently infected CD4+ T cells under antiretroviral therapy
is themajor obstacle to an HIV-1 cure. Recently published inNature, two seminal studies fromDescours et al.
(2017) and Nishimura et al. (2017) bring hope for tracking and possibly eradicating the HIV-1 reservoir.The main challenge facing a curative
approach for HIV-1 infection is the exis-
tence of latently infected cells harboring
immunologically silent but replication-
competent proviruses. This latent reser-
voir is established very rapidly upon
HIV-1 infection, persists in patients
despite antiretroviral therapy (ART), and
is likely to cause viral rebound after ART
cessation. The scientific community has
envisaged various strategies to tackle
the ‘‘reservoir’’ roadblock (Deeks et al.,
2016), especially those aimed at elimi-
nating latently infected T cells. The lead
idea, termed ‘‘shock and kill’’ therapy,
proposes reverting HIV-1 latency with
the use of viral inducers to enable the
destruction of infected cells via virus-
induced cytopathic effects and/or, most
likely, immune-based cytolysis (Deeks
et al., 2016). In accordance with the
‘‘shock and kill’’ theory, broadly neutral-
izing antibodies (bNAbs) combined with
viral inducers have been shown to sub-
stantially decrease the HIV-1 reservoir in
humanized mice and also to interfere
with its establishment when injected
alone early after infection (Halper-Strom-berg et al., 2014). But so far, research
investigations and therapeutic inter-
ventions on the HIV-1 reservoir have
been rendered extremely difficult, mostly
because of the lack of selective bio-
markers to phenotypically identify latently
infected cells. In a landmark study pub-
lished in Nature, Descours et al. identified
a membrane protein, the immunoglobulin
G (IgG) receptor CD32a, as specifically
induced at the surface of quiescent CD4+
T cells infected by HIV-1 (Descours et al.,
2017). On the therapeutic side, in the
same issue of Nature, Nishimura et al.
show that early treatment of simian-
human immunodeficiency virus (SHIV)-in-
fected macaques with a combination of
twobNAbscould lead to long-termcontrol
of infection (Nishimura et al., 2017).
Building on their original work identi-
fying SAMHD1 as a restriction factor
blocking HIV-1 replication (Laguette
et al., 2011), Benkirane and colleagues
developed an elegant in vitro system to
study latently infected CD4+ T cells.
They identified a set of about 100 genes
upregulated in latently HIV-1-infected
cells, including 16 coding for transmem-brane proteins (Descours et al., 2017).
Among them, CD32a, a low-affinity recep-
tor for IgG Fc fragment (also called
FcgRIIa), showed the highest specific
expression on quiescent T cells infected
in vitro. In ART-treated patients, on
average half of the reservoir’s CD4+
T cells expressed CD32a, and these
CD32a+ cells did carry replication-
competent provirus (Descours et al.,
2017). This seminal discovery opens
doors for a deeper understanding of the
HIV-1 reservoir biology but also many
new interrogations. One burning question
for immunologists is the significance of
the induced expression of the FcgRIIa
on latent T cells infected with HIV-1.
Does CD32a have a functional role, or is
its induction just a bystander effect of
HIV-1 integration in quiescent cells and
subsequent cellular pathway activation?
Because binding of IgG immune com-
plexes to FcgRIIa normally triggers the
activation of CD32a+ innate effector cells,
the reason for its expression on the HIV-1
reservoir’s T lymphocytes is obscure.
With respect to the functional cure
concept, could CD32a be safely used as46, April 18, 2017 ª 2017 Elsevier Inc. 527
